Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Schott Pharma Earnings Release 2025

May 14, 2024

6514_rns_2024-05-14_837b86f3-1d27-4a27-9906-5386480628d0.html

Earnings Release

Open in viewer

Opens in your device viewer

News Details

Ad-hoc | 14 May 2024 18:03

SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes

SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast

SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes

14-May-2024 / 18:03 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


SCHOTT Pharma see FY 25 impacted by slower growth from syringes

For its fiscal year 2024/2025, beginning 1 st October 2024, the company is forecasting a revenue growth in a high single-digit to a low double-digit percentage range, which deviates from the current market consensus. Due to the revenue growth that is lower than previously expected, the EBITDA margin expansion will be weaker than currently expected in the market.

These forecasts are based on constant currencies.

The reason for the expected development in fiscal year 2024/2025 is a lower demand for syringes of a large customer.

Despite this temporary effect, the company confirms its mid-term forecast. The company also confirms its forecast for the current fiscal year.

Investor contact

Jasko Terzic, CFA

Senior Investor Relations Manager

E-Mail: [email protected]

Press contact

Joana Kornblum

Media Relations

Tel.: +49 151/29223552

E-Mail: [email protected]

End of Inside Information


14-May-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com


Language: English
Company: SCHOTT Pharma AG & Co. KGaA
Hattenbergstraße 10
55122 Mainz
Germany
ISIN: DE000A3ENQ51
WKN: A3ENQ5
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
EQS News ID: 1902981
End of Announcement EQS News Service

show this